多层螺旋CT在肺腺癌化疗中的应用

目的观察肺腺癌化疗前后肿瘤标志物及CT影像学变化特点。方法收集我院2012年5月-2015年4月收治的56例肺腺癌患者,所有患者均接受化疗治疗,均于化疗前后采用化学发光法测定血清肿瘤标志物甲胎蛋白(AFP)、癌胚抗原(CEA)、糖类抗原(CA125、CA199、CA153)浓度水平变化,同时行肺部CT影像学检查,分析肺腺癌化疗前后肿瘤标志物及CT影像学变化特征。结果化疗4个周期后,肺腺癌患者血清肿瘤标志物AFP、CEA、CA125、CA199、CA153均明显降低,与化疗前对比差异有统计学意义(P0.05);化疗4个周期后,完全缓解8例,部分缓解28例,稳定18例,进展2例。有效共36例(64.29%),进展20例(35.71%),有效组AFP、CEA、CA125、CA199、CA153水平均明显低于进展组(P0.05)。结论化疗后,肺腺癌患者血清肿瘤标志物变化与CT影像学变化有其较高的一致性,对部分CT检查无法评估的患者,可辅以血清肿瘤标志物检查,为治疗方式的调整提供指导。

Tumor Markers and CT Imaging Changes Before and After Chemotherapy for Lung Adenocarcinoma

Objective To observe the changes of tumor markers and CT imaging before and after chemotherapy of lung adenocarcinoma.Methods 56 cases of patients with lung adenocarcinoma who admitted in our hospital between May 2012 and April 2015 were included into the study. All patients were treated with chemotherapy. The serum tumor markers such as alpha-fetal protein (AFP), carcino-embryonic antigen (CEA), carbohydrate antigen (CA125, CA199, CA153) which determined by chemiluminescence method were recorded before and after chemotherapy. Meanwhile, pulmonary CT imaging examination was performed. The changes of tumor markers and CT imaging before and after chemotherapy of lung adenocarcinoma were analyzed.Results After 4 cycles of chemotherapy, the serum tumor markers such as AFP, CEA, CA125, CA199 and CA153 decreased significantly. Compared with those before chemotherapy, there were statistically significant differences (P<0.05), after 4 cycles of chemotherapy, there were 8 cases completely remitted, 28 cases partially remitted, 18 cases stable and 2 cases in progression. There were a total of 36 cases (64.29%) effective and 20 cases (35.71%) in progression. Levels of tumor markers such as AFP, CEA, CA125, CA199 and CA153 in effective group were significantly lower than those in the progression group (P<0.05). Conclusion After chemotherapy, the changes of serum tumor markers and CT imaging in patients with lung adenocarcinoma were relatively higher consistency. For some patients whom CT examination cannot evaluate, serum tumor marker can be used to help examination, so as to provide guidance for the adjustment of treatment.